Loading…
Reported covered position: LA/CONG WATTS
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S. 1712)
Prescription Drug Pricing Reduction Act of 2020
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S. 1712)
Source: Senate LDA
Prescription Drug Pricing Reduction Act (PDPRA) (S. 4199); Pharmaceutical intellectual property issues
Prescription Drug Pricing Reduction Act of 2020
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S. 1712)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Intellectual property; HR 3497
Intellectual property; HR 3497
Intellectual property issues; HR 3497
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Hospital discounts (HR 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Hospital discounts (HR 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Hospital discounts (HR 3590)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Hospital discounts (HR 3590)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Finanical derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
340B Program Improvement and Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
Electric Drive Vehicle Deployment Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access (HR 5442)
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Wall Street Reform and Consumer Protection (HR 4173)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Transparency (HR 1669)
Transparency (HR 1669)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
TRUST in Health Information Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access (HR 5442)
TRUST in Health Information Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access (HR 5442)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Medicare Improvements for Patients and Providers Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
Prescription Drug Pricing Reduction Act (PDPRA) (S. 4199); Pharmaceutical intellectual property issues
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · first_quarter · Q1
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Implementation of the Tax Cuts and Jobs Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Prescription Drug Pricing Reduction Act (PDPRA)
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · fourth_quarter · Q4
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Prescription Drug Pricing Reduction Act (PDPRA)
Intellectual property; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Implementation of the Tax Cuts and Jobs Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Hatch Waxman Integrity Act
Implementation of the Tax Cuts and Jobs Act
Intellectual property; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value; Senate Finance bill; Prescription Drug Pricing Reduction Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · 2A
Implementation of the Tax Cuts and Jobs Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Intellectual property; Dormant Therapies Act; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value
Hatch Waxman Integrity Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · Q2
Implementation of the Tax Cuts and Jobs Act
Intellectual property; Dormant Therapies Act; 340B Program; PPACA
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · first_quarter · Q1
Intellectual property; Dormant Therapies Act; 340B Program; PPACA
Hatch Waxman Integrity Act
Implementation of the Tax Cuts and Jobs Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · 1A
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession; Saudi Arabia
Implementation of the Tax Cuts and Jobs Act
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · 3A
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Implementation of the Tax Cuts and Jobs Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · Q3
Intellectual property
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · second_quarter · Q2
Implementation of the Tax Cuts and Jobs Act
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · Q1
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Intellectual property
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Tax reform
Intellectual property
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · Q4
Tax reform
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · 3A
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · second_quarter · Q2
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Tax reform
Intellectual property; MODDERN cures
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · first_quarter · Q1
Tax reform
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · fourth_quarter · Q4
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B; Medicare Part D, PPACA
Tax reform
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · third_quarter · Q3
Intellectual property; MODDERN Cures
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · Q2
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · first_quarter · Q1
Intellectual property; MODDERN Cures
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Tax reform
Intellectual property; MODDERN Cures
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Intellectual property; MODDERN Cures
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · second_quarter · Q2
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; MODDERN Cures
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · first_quarter · Q1
Intellectual property; MODDERN Cures
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · 4A
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · Q4
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · third_quarter · Q3
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Tax retorm
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
Tax retorm
Intellectual property; HR 3497
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Intellectual property; HR 3497
Tax retorm
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Tax reform
Intellectual property; HR 3497
Anti-counterfeiting; Patent safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Intellectual property; HR 3497
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Intellectual property; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
Intellectual property; HR 3497
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Intellectual property; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
Intellectual property issues; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
Intellectual Property Issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
Patent Reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Patent reform; Anti-counterfeiting; Patient Safety
Bipartisian Tax Fairness and Simplification Act (S727)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
Corporate Tax Reform, Patent Reform (S 23, HR 1249)
The America Invents Act of 2011 (HR 1249), BiPartisan Tax Fairness and Simplifiation Act (S 727)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · fourth_quarter · Q4
Financial derivatives (HR 4173)
Hospital discounts (HR 3590)
Financial derivatives (HR 4173)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
Hospital discounts (HR 3590)
Financial derivatives (HR 4173)
Financial derivatives (HR 4173)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Financial derivatives (HR 4173)
Hospital discounts (HR 3590)
Financial derivatives (HR 4173)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
Financial derivatives (HR 4173)
Hospital discounts (HR 3590)
Financial derivatives
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Wall Street Reform and Consumer Protection (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · third_quarter · Q3
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Health Care Reform, Comparative Effectiveness (S 1213, HR 2502, S 1259)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Access (HR 5442)
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · 2A
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · 1A
Transparency (HR 1669)
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
Medicare, Medicaid
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Waxman Medicare Part D non-interference,
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · Q1
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Access (HR 5442)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2005 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Hatch Waxman Integrity Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hatch Waxman Integrity Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hatch Waxman Integrity Act
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Implementation of the Tax Cuts and Jobs Act
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; Dormant Therapies Act; 340B Program; Bipartisian Budget of 2018; PPACA
Intellectual property
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Tax reform
Intellectual property
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Tax reform
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN cures
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Promoting Public-Private Partnerships; UN High Level Panel on Access to Medicines (UNHLP) and Other Multi-lateral Threats to IP and the Biopharmaceutical Industry
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Intellectual property; MODDERN Cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN Cures
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Finanical derivatives (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Financial derivatives (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Financial derivatives (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Financial derivatives (HR 4173)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Access (HR 5442)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Transparency (HR 1669)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)